当地时间2023年10月20日至24日，肿瘤领域一年一度的学术盛会——欧洲肿瘤内科学会（ESMO）年会将于西班牙马德里盛大召开，可谓备受关注。日前，ESMO官方已公布除Late-breaking abstracts（LBAs）外的所有口头摘要题目及作者信息。
针对NET及内分泌肿瘤专场，【肿瘤资讯】整理了论文优选专场（Proffered Paper Session）、简短口头报告专场（Mini Oral Session）的相关研究摘要信息，与读者分享。
论文优选专场
Proffered Paper Session
摘要号：723O
卡博替尼联合阿替利珠单抗治疗晚期和进展性内分泌系统肿瘤：一项多队列篮子II期试验（CABATEN / GETNE-T1914）
Cabozantinib plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System: A multi-cohort Basket Phase II Trial (CABATEN / GETNE-T1914)
讲者：Jaume Capdevila Castillon|Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain
摘要号：1182O
替莫唑胺治疗在高分化胰腺神经内分泌肿瘤中诱导MMR依赖性高突变表型
Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors
讲者：Louis De Mestier du Bourg |Beaujon Hospital APHP, Clichy, France
摘要号：724O
EOADR1-19/SPENCER研究：EO2401（E）肽免疫疗法+纳武利尤单抗（N）治疗肾上腺皮质癌（ACC）和转移性嗜铬细胞瘤/副神经节瘤（MPP）
EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP); EOADR1-19/SPENCER
讲者：Eric Baudin|Gustave Roussy, Villejuif, France
简短口头报告专场
Mini Oral Session
摘要号：2211MO
揭示RET突变甲状腺癌持续疾病机制：来自患者源异种移植模型经选择性RET抑制剂治疗的见解
Uncovering the Mechanisms of Persistent Disease in RET-altered Thyroid Cancers: Insights from Patient-Derived Xenograft Models treated with Selective RET Inhibitors.
讲者：Alejandro Garcia Alvarez|Vall d'Hebron University Hospital, Barcelona, Spain
摘要号：1183MO
通过多组学分析对预后不良的直肠神经内分泌肿瘤（NETs）进行分子特征化：一项多中心回顾性队列研究（GARNET）
Molecular characterization of rectal neuroendocrine tumors (NETs) with unfavorable prognosis by multiomics analysis: A multicenter retrospective cohort study (GARNET)
讲者：Taro Shibuki|National Cancer Center Hospital East, Chiba, Japan
摘要号：1184MO
一项AIO II期研究（EVINEC）：依维莫司（EVE）作为G3级神经内分泌肿瘤（NEN G3）二线治疗的安全性和有效性
Safety and efficacy of everolimus (EVE) as second–line treatment in neuroendocrine neoplasms G3 (NEN G3) - an AIO phase II study (EVINEC)
讲者：Marianne E. Pavel|Universitätsklinik Erlangen, Erlangen, Germany
摘要号：1185MO
Avelumab单独或联合卡博替尼用于化疗经治进展后的晚期高级别神经内分泌肿瘤（NEN G3）患者的活性和安全性：II期开放标签、多中心AVENEC和CABOAVENEC试验
Activity and safety of avelumab alone or in combination with cabozantinib in patients with advanced high grade neuroendocrine neoplasias (NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter AVENEC and CABOAVENEC trials.
讲者：Matthias M. M. Weber|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
摘要号：725MO
DLL3/CD3 IgG样T细胞结合物BI764532在DLL3阳性肿瘤患者的I期试验：关注神经内分泌癌
Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas
讲者：Valentina Gambardella (Valencia, Spain)
摘要号：1186MO
胰腺神经内分泌肿瘤采用177Lu-DOTATATE肽受体放射性核素治疗（PRRT）新辅助后手术的前瞻性II期单臂试验（NeoLuPaNET）
A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE Followed by Surgery for Pancreatic Neuroendocrine Tumors (NeoLuPaNET)
讲者：Stefano Partelli |UniSR - Università Vita e Salute San Raffaele Milano,Milan, Italy
摘要号：2212MO
多中心非劣效随机试验IoN中的主要次要结局：对于低风险分化型甲状腺癌患者，放射性碘消融是否必要？
Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radiOiodine Necessary for low risk differentiated thyroid cancer patients?
讲者：Allan Hackshaw |Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom
摘要号：1187MO
ENDOCAN-COMETE网络是否能提高法国肾上腺皮质癌患者的生存率？
Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France?
讲者：Rossella L. Libe|Hopital Cochin - Site Port-Royal AP-HP, Paris, France
（本文依照报告日期和出场排序整理，如有错误或遗漏，敬请留言指正。）
https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/calendar/2023-10-22?r=pt%7E19_63
排版编辑：肿瘤资讯-Astrid
苏公网安备32059002004080号
